Patient Perspective as Integral Part of the Drug Life Cycle
There is an increasing consensus among researchers, drug developers, regulators and patients that patient engagement is critical to fostering patient access to innovative therapies, and delivering better health outcomes for patients.
We are delighted to welcome Conny Berlin, Dipl.-Math., Global Head Quantitative Safety & Epidemiology, Novartis International AG.
| Date: | 28th February 2018 |
|---|---|
| Time: | 17.00 h to 18.00 h |
| Location: | HS 9 |
Patient Perspective as Integral Part of the Drug Life Cycle
There is an increasing consensus among researchers, drug developers, regulators and patients that patient engagement is critical to fostering patient access to innovative therapies, and delivering better health outcomes for patients. However, it has been acknowledged that an appropriate structured approach, including a set of systematic methodologies and recommendations for their use, is needed. The Innovative Medicines Initiative PREFER will be introduced and it will be presented how patient preference studies can contribute to patient-centric decision making.
Lecture Series Spring 2018: The Patient's Voice in Drug Development
In this lecture series, professionals from industries, adademia and patient organizations will share their visions how the patient perspective can become an integral part of the drug development process, and how this relates to public interests, regulatory requirements, the law and international initiatives.
